Treatment Details – 23.0 months
|Patients: This phase II study involved 30 patients with malignant pleural mesothelioma. The average age was 66, ranging from 49 to 84 years of age. There were 25 men and 5 women.|
Treatment: Patients had surgery and were treated with Tetrathiomolybdate. This is a biological therapy that affects copper levels and the development of new blood vessels (angiogenesis).
Toxicity: Many patients (53%) felt dizzy, but the dizziness was not related to any changes in blood pressure. Most (90%) of the patients reported grade 1 or 2 fatigue. Grade 3 granulocytopenia, anemia, and thrombocytopenia were also reported. The most common grade 3 toxicity was granulocytopenia, reported in 40% of the patients.
Results: The median overall survival was 23 months. For patients with stage I and II disease, the median survival time was 41 months, and for those with stage III disease, it was 15 months.
Support: This study was supported in part by funds from Attenuon LLC, a company which liscened the drug used in this study from the University of Michigan.
Correspondence: Dr. Harvey Pass